Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221113020> ?p ?o ?g. }
- W4221113020 abstract "Abstract Background Neuroblastoma (NB) is a common extracranial malignancy with high mortality in children. Recently, super-enhancers (SEs) have been reported to play a critical role in the tumorigenesis and development of NB via regulating a wide range of oncogenes Thus, the synthesis and identification of chemical inhibitors specifically targeting SEs are of great urgency for the clinical therapy of NB. This study aimed to characterize the activity of the SEs inhibitor GNE987, which targets BRD4, in NB. Results In this study, we found that nanomolar concentrations of GNE987 markedly diminished NB cell proliferation and survival via degrading BRD4. Meanwhile, GNE987 significantly induced NB cell apoptosis and cell cycle arrest. Consistent with in vitro results, GNE987 administration (0.25 mg/kg) markedly decreased the tumor size in the xenograft model, with less toxicity, and induced similar BRD4 protein degradation to that observed in vitro. Mechanically, GNE987 led to significant downregulation of hallmark genes associated with MYC and the global disruption of the SEs landscape in NB cells. Moreover, a novel candidate oncogenic transcript, FAM163A , was identified through analysis of the RNA-seq and ChIP-seq data. FAM163A is abnormally transcribed by SEs, playing an important role in NB occurrence and development. Conclusion GNE987 destroyed the abnormal transcriptional regulation of oncogenes in NB by downregulating BRD4, which could be a potential therapeutic candidate for NB." @default.
- W4221113020 created "2022-04-03" @default.
- W4221113020 creator A5004751003 @default.
- W4221113020 creator A5007368418 @default.
- W4221113020 creator A5014859221 @default.
- W4221113020 creator A5017255913 @default.
- W4221113020 creator A5019881817 @default.
- W4221113020 creator A5022442454 @default.
- W4221113020 creator A5022492093 @default.
- W4221113020 creator A5024124240 @default.
- W4221113020 creator A5028399555 @default.
- W4221113020 creator A5038764555 @default.
- W4221113020 creator A5039626583 @default.
- W4221113020 creator A5039962459 @default.
- W4221113020 creator A5041530674 @default.
- W4221113020 creator A5043490198 @default.
- W4221113020 creator A5049692788 @default.
- W4221113020 creator A5053523358 @default.
- W4221113020 creator A5066332067 @default.
- W4221113020 creator A5068676227 @default.
- W4221113020 creator A5069945011 @default.
- W4221113020 creator A5075179075 @default.
- W4221113020 creator A5077293354 @default.
- W4221113020 creator A5080059087 @default.
- W4221113020 creator A5080278932 @default.
- W4221113020 creator A5082475531 @default.
- W4221113020 creator A5090937608 @default.
- W4221113020 date "2022-03-18" @default.
- W4221113020 modified "2023-10-13" @default.
- W4221113020 title "BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma" @default.
- W4221113020 cites W1516500631 @default.
- W4221113020 cites W1965425724 @default.
- W4221113020 cites W1971578941 @default.
- W4221113020 cites W1992127633 @default.
- W4221113020 cites W2004966039 @default.
- W4221113020 cites W2017162138 @default.
- W4221113020 cites W2060484997 @default.
- W4221113020 cites W2079407198 @default.
- W4221113020 cites W2091517552 @default.
- W4221113020 cites W2092722989 @default.
- W4221113020 cites W2110735746 @default.
- W4221113020 cites W2155538826 @default.
- W4221113020 cites W2161535481 @default.
- W4221113020 cites W2161577298 @default.
- W4221113020 cites W2170846478 @default.
- W4221113020 cites W2171556712 @default.
- W4221113020 cites W2176436801 @default.
- W4221113020 cites W2183670742 @default.
- W4221113020 cites W2191516082 @default.
- W4221113020 cites W2237051895 @default.
- W4221113020 cites W2342055991 @default.
- W4221113020 cites W2383217883 @default.
- W4221113020 cites W2470378304 @default.
- W4221113020 cites W2584822160 @default.
- W4221113020 cites W2586373162 @default.
- W4221113020 cites W2593459113 @default.
- W4221113020 cites W2738563754 @default.
- W4221113020 cites W2760574993 @default.
- W4221113020 cites W2776596084 @default.
- W4221113020 cites W2886540393 @default.
- W4221113020 cites W2889489530 @default.
- W4221113020 cites W2900251974 @default.
- W4221113020 cites W2900679912 @default.
- W4221113020 cites W2913761875 @default.
- W4221113020 cites W2920620505 @default.
- W4221113020 cites W2921841818 @default.
- W4221113020 cites W2936661052 @default.
- W4221113020 cites W2947733174 @default.
- W4221113020 cites W2952630532 @default.
- W4221113020 cites W2964989542 @default.
- W4221113020 cites W2967818455 @default.
- W4221113020 cites W2973926462 @default.
- W4221113020 cites W2987062778 @default.
- W4221113020 cites W2987291349 @default.
- W4221113020 cites W2995454807 @default.
- W4221113020 cites W2999161782 @default.
- W4221113020 cites W2999764480 @default.
- W4221113020 cites W3007327029 @default.
- W4221113020 cites W3018696360 @default.
- W4221113020 cites W3027679488 @default.
- W4221113020 cites W3043129676 @default.
- W4221113020 cites W3083716544 @default.
- W4221113020 cites W3103778988 @default.
- W4221113020 cites W3108222024 @default.
- W4221113020 cites W3112248352 @default.
- W4221113020 cites W3149585839 @default.
- W4221113020 cites W3159539838 @default.
- W4221113020 cites W3160556876 @default.
- W4221113020 cites W3202693025 @default.
- W4221113020 cites W3205562405 @default.
- W4221113020 cites W4211078399 @default.
- W4221113020 doi "https://doi.org/10.1186/s13578-022-00769-8" @default.
- W4221113020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35303940" @default.
- W4221113020 hasPublicationYear "2022" @default.
- W4221113020 type Work @default.
- W4221113020 citedByCount "8" @default.
- W4221113020 countsByYear W42211130202022 @default.
- W4221113020 countsByYear W42211130202023 @default.
- W4221113020 crossrefType "journal-article" @default.
- W4221113020 hasAuthorship W4221113020A5004751003 @default.